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a b s t r a c t
Type 1 diabetes (T1D) is a multigenic disease caused by T-cell mediated destruction of the insulin
producing pancreatic islet β-cells. The earliest sign of islet autoimmunity in NOD mice, islet leukocytic
inﬁltration or insulitis, is obvious at around 5 weeks of age. The molecular alterations that occur in T cells
prior to insulitis and that may contribute to T1D development are poorly understood. Since CD4 T-cells
are essential to T1D development, we tested the hypothesis that multiple genes/molecular pathways are
altered in these cells prior to insulitis. We performed a genome-wide transcriptome and pathway
analysis of whole, untreated CD4 T-cells from 2, 3, and 4 week-old NOD mice in comparison to two
control strains (NOR and C57BL/6). We identiﬁed many differentially expressed genes in the NOD mice at
each time point. Many of these genes (herein referred to as NOD altered genes) lie within known
diabetes susceptibility (insulin-dependent diabetes, Idd) regions, e.g. two diabetes resistant loci, Idd27
(tripartite motif-containing family genes) and Idd13 (several genes), and the CD4 T-cell diabetogenic
activity locus, Idd9/11 (2 genes, KH domain containing, RNA binding, signal transduction associated 1 and
protein tyrosine phosphatase 4a2). The biological processes associated with these altered genes
included, apoptosis/cell proliferation and metabolic pathways (predominant at 2 weeks); inﬂammation
and cell signaling/activation (predominant at 3 weeks); and innate and adaptive immune responses
(predominant at 4 weeks). Pathway analysis identiﬁed several factors that may regulate these
abnormalities: eight, common to all 3 ages (interferon regulatory factor 1, hepatic nuclear factor 4,
alpha, transformation related protein 53, BCL2-like 1 (lies within Idd13), interferon gamma, interleukin 4,
interleukin 15, and prostaglandin E2); and two each, common to 2 and 4 weeks (androgen receptor and
interleukin 6); and to 3 and 4 weeks (interferon alpha and interferon regulatory factor 7). Others were
unique to the various ages, e.g. myelocytomatosis oncogene, jun oncogene, and amyloid beta (A4) to
2 weeks; tumor necrosis factor, transforming growth factor, beta 1, NFκB, ERK, and p38MAPK to 3 weeks;
and interleukin 12 and signal transducer and activator of transcription 4 to 4 weeks. Thus, our study
demonstrated that expression of many genes that lie within several Idds (e.g. Idd27, Idd13 and Idd9/11)
was altered in CD4 T-cells in the early induction phase of autoimmune diabetes and identiﬁed their
associated molecular pathways. These data offer the opportunity to test hypotheses on the roles played
by the altered genes/molecular pathways, to understand better the mechanisms of CD4 T-cell
diabetogenesis, and to develop new therapeutic strategies for T1D.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Type 1 (autoimmune) diabetes (T1D) is a multigenic disease
that, in humans and NOD mice, results from T-cell mediated
destruction of insulin producing beta cells in the pancreatic islets
[1–4]. Insulitis, the earliest sign of autoimmune pathology in the
pancreas of NOD mice, in our colony becomes obvious at around
5 weeks of age, at which stage accumulation of leukocytes is
observed around the pancreatic islets. This process progressively
intensiﬁes leading to T lymphocytic inﬁltration of the pancreatic
islets and eventual massive destruction of the insulin producing
beta cells with clinical disease occurring at 12 weeks of age or
later. The molecular alterations that occur in T cells prior to
insulitis and that may contribute to T1D pathogenesis are poorly
understood.
It is well established that genetic predisposition is a major factor in
the etiology of T1D. The major histocompatibility (MHC) class II
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molecule H2-Ag7 in NOD mice (or HLA-DQ2 and -DQ8 in humans) is
the strongest genetic determinant for T1D development [1–4]. The
MHC class II-restricted CD4 T-cells are essential for the development of
autoimmune diabetes [2,5]. To this end, (1) CD4 T-cells from spleens of
NOD mice are reactive to pancreatic beta cell antigens [6]; (2)
Spleen CD4 T-cells from NOD mice can transfer diabetes to young
NOD and NOD.scidmice [7,8]; (3) NODmice lacking CD4 T-cells do not
develop diabetes [9]. Reconstitution of these mice with NOD spleen
CD4 T-cells leads to development of diabetes [5,10]; and (4)
transgenic NOD mice harboring CD4 T-cells with T cell receptor
reactive to islet antigens develop insulitis and diabetes [8]. The
chromosomal regions that modulate T1D susceptibility in NOD mice
are designated insulin-dependent diabetes regions (Idd). In conjunc-
tion with the MHC locus, which is required but alone insufﬁcient for
T1D development, over 20 non-MHC Idd loci also contribute to the
disease process in NOD mice [3,4,11–14]. Although, the identities of
some of the non-MHC Idd genes that interactively contribute to the
diabetogenic process in CD4 T-cells of NOD mice have been revealed
[5,10,15–19], most of these genes and/or their interactions remain
unknown.
The conventional approach in the ﬁeld to understanding the
pathogenesis of T1D has been mainly via targeted analysis at the
individual gene or loci level. Identiﬁcation of all the genes that
together cause diabetes (a multigenic disease) via these approaches
can be tortuous as each gene may only contribute weakly to the
pathology. While these approaches have yielded useful information
on how identiﬁed genes may interact with each other to confer
disease susceptibility and/or protection, a whole cellular and/or
molecular systems analysis (non-targeted approach) provides the
opportunity to simultaneously interrogate the genes/pathways that
are involved in the disease process [20]. A comprehensive under-
standing of these molecular interactions is important because it is
now clear that the best targets for development of novel prevention
and/or treatment interventions for complex trait diseases may not be
the disease associated genes per se but rather their interaction
partners, upstream regulators or downstream targets, or the mole-
cular network [21–24]. Thus, to gain insights into the molecular
networks that might play a role in the diabetogenic activity of CD4 T-
cells in the early induction phase of T1D, we evaluated the tran-
scriptomes of untreated, whole CD4 T-cells collected from the
spleens of NOD mice in the period prior to overt insulitis and
inferred the associated altered molecular networks using a suite of
complementary bioinformatics tools.
2. Materials and methods
2.1. Mice, sample collection and microarray procedures
Animal procedures were approved by the University of Tennessee
(UT) Health Science Center and Veteran Affairs (VA) Medical Center
Animal Care and Use Committee (Protocol Numbers: UT 1159/VA
00157). Breeder micewere purchased from the Jackson Laboratory and
housed at the VA animal facility. Spleen leukocytes were collected, as
described previously [25,26] from female NOD mice at 2, 3 and
4 weeks of age (representing the period prior to overt insulitis) and
from two matched control strains, NOR and C57BL/6 (C57); n¼5 for
each strain and age group, except NOD 2 week, where n¼4. CD4 T-
cells were then negatively separated by magnetic beads according to
the manufacturer’s protocol (Miltenyi Biotec). Purity was assessed by
ﬂow cytometry using FITC-conjugated anti-mouse CD4 monoclonal
antibodies (Becton Dickinson); only samples of 490% purity were
used in the study. Total RNAwas extracted from untreated, whole CD4
T-cells, as described previously [26,27]. A total of 1–1.5 mg of total RNA
was processed with Two-Cycle Target labeling protocol and hybridized
on Affymetrix, Mouse430_2 expression arrays, according to the
manufacturer’s instructions. Normalization, scaling, and basic evalua-
tion of the quality of the expression data from each chip were
conducted using the GCOS software (Affymetrix), as described pre-
viously [25,26]. The microarray data sets are available in the gene
expression omnibus repository [GSE46600]. Microarray results were
validated by quantitative Real-time PCR, as described previously [25]
(Fig. S1). Expression values were normalized to glyceraldehyde-3-
phosphate dehydrogenase (Gapdh). The target genes, primers and
probes are listed in Table S1.
2.2. Statistical analysis
Statistical analysis of the microarray data was conducted as
previously described [25,26]. Filtration of the probe sets present
on the chip array (60,000) identiﬁed 31,000 probe sets that
had a present/marginal expression ﬂag in at least one of the
samples. We then performed one-way ANOVA (at various statis-
tical stringencies) on the ﬁltered probe sets for each age separately
in order to deﬁne lists of age-speciﬁc genes that were differentially
expressed between strains. Lists generated at either po0.005
("smaller" list) or p o 0.05 ("larger" list) adjusted with Benja-
mini–Hochberg multiple test correction (corresponding to a false
discovery rate (FDR) of 0.5% or 5%, respectively) were used in
further analysis. Finally, we conducted hierarchical clustering on
these lists as previously described [27] to identify genes that were
uniquely differentially expressed in NOD mice relative to both
control strains. These genes are herein referred to as NOD
altered genes.
2.3. Data mining analyses
We subjected the lists of NOD altered genes to data mining
using a suite of modern bioinformatics tools. Enriched gene
ontology (GO) categories and KEGGs pathways were determined
using WebGestalt Gene Set Analysis Toolkit (http://bioinfo.vander
bilt.edu/webgestalt [28]), as described previously [25]. To identify
transcription regulators whose binding sites were signiﬁcantly
over-represented in the promoters of the NOD altered gene sets,
we used the PRIMA (PRomoter Integration in Microarray Analysis)
program of the EXPANDER suite (EXpression Analyzer and Dis-
playER; http://acgt.cs.tau.ac.il/expander/overview.html; Tel Aviv
University, Israel). PRIMA achieves this by utilizing known models
for transcription factor binding sites. Corresponding transcription
regulators are considered to be candidate regulators of the
corresponding set of genes. We used Ingenuity Pathway Analysis
(IPA, http://www.ingenuity.com) as described in detail previously
[25] to identify de novo molecular networks that are associated
with the NOD altered genes.
3. Results
3.1. Genes differentially expressed in NOD CD4 T-cells at the
preinsulitis stage of autoimmune diabetes
We compared the whole genome mRNA expression in CD4 T-
cells from 2-, 3-, and 4-week old NOD mice to that of two matched
control strains, NOR and C57BL/6 (C57). NOR shares 88% of its
genome with NOD mice, including the diabetogenic H2g7 MHC
haplotype and several important non-MHC T1D susceptibility loci
[1–4,29]. C57, on the other hand, is a more genetically distantly
related strain to NOD. Yet, like C57, NOR is both insulitis- and
diabetes-free.
We identiﬁed 362, 982, and 581 probe sets (genes) with highly
signiﬁcant expression differences between strains (p o 0.005, Benja-
mini–Hochberg; FDR of 0.5%) at 2, 3, and 4 weeks, respectively. As
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expected, the majority of these genes had a similar pattern of
expression in NOD and NOR compared to C57 (Fig. 1). The focus of
our study was to identify genes in NOR mice whose expression was
similar to that in C57 but different from that in NOD, i.e. genes
differentially expressed in NOD relative to both NOR and C57, and
herein referred to as NOD altered genes. These constitute prospective
candidate genes for protection of NOR mice against diabetes. Thus, we
identiﬁed a total of 58, 115, and 65 probe sets whose expression was
altered in NOD at 2, 3 and 4 weeks, respectively, compared to both
controls (clusters of lower or higher expression in NOD are indicated
by arrows in Fig. 1). These represented 56, 107, and 60 different genes,
respectively, shown in Tables 1–4. The great majority of these genes
were of lower expression in NODmice compared to controls: 70% at
2 weeks; 72% at 3 weeks; and 87% at 4 weeks. Twenty-ﬁve genes
(72% of which was of lower expression in NODmice) were common to
all 3 ages. Results for qRT-PCR validation of eight genes are shown in
Fig. S1 (3 of higher expression in NOD mice: protein tyrosine
phosphatase 4a2 (Ptp4a2), biogenesis of organelles complex-1, subunit
6 (Bloc1s6, pallidin) and transmembrane protein 87A (Tmem87a); and
5 of lower expression in NOD mice: tripartite motif-containing 5
(Trim5), tripartite motif-containing 12A (Trim12a), Gatm (glycine
amidinotransferase (L-arginine:glycine amidinotransferase)), lympho-
cyte antigen 6 complex, locus C1 (Ly6c1), and receptor transporter
protein 4 (Rtp4) compared to control mice). The major selected
functional categories (as determined by the authors based on informa-
tion obtained from literature searches) included immune response,
apoptosis/cell proliferation, transcription, zinc-ion binding, protein/
nucleic acid binding, "Other enzymes" for enzymes not already
assigned to a speciﬁc category, and "Other" for genes that did not fall
in one major category. Probe sets of unknown identiﬁcation/function
are listed under "Unknown". Based on these categories, a higher
percentage of NOD altered genes (22%) were involved in apoptosis/
cellular proliferation at each of 2 or 3 weeks than at 4 weeks (12%).
Conversely, a higher percentage of genes (22%) were involved in
immune response at 4 weeks than at 2 or 3 weeks (4.1% and 12%,
respectively). Overall, a high percentage of genes at all 3 ages were
involved in enzymatic activity, including several kinases/phosphatases
at 3 weeks. Moreover, a large number of the CD4 T-cell NOD altered
genes lie within known Idds, 52%, 47% and 38% at 2, 3, and 4 weeks,
respectively (Tables 1–4). A total of 14 (25%), 20 (19%) and 10
(17%) genes at 2, 3, and 4 weeks, respectively, lie within Idd13, a
region located on chromosome (Chr) 2 and previously identiﬁed to
confer resistance to diabetes in NOR mice [4,15–17,30]. These genes
included 6 that were common to all 3 ages: Bloc1s6, Trp53bp1
(transformation related protein 53 binding protein 1), Tmem87a,
Ctdspl2 (CTD (carboxy-terminal domain, RNA polymerase II, polypep-
tide A) small phosphatase like 2), Gatm and Raly (hnRNP-associated
with lethal yellow). Two genes (Khdrbs1  KH domain containing,
RNA binding, signal transduction associated 1 and Ptp4a2, both altered
at 2 and 3 weeks, but only Khdrbs1 at 4 weeks) lie within Idd9/11, a
region on Chr4 that also confers resistance to diabetes in NOR. This
region has also been demonstrated previously by several groups to
regulate the diabetogenic activity of CD4 T-cells [5,10,18,19].
3.2. Gene ontology categories and KEGG pathways of the CD4 T-cell
NOD altered genes
To gain further insights into the biological processes associated
with the NOD altered genes, we performed Gene ontology (GO)
and KEGG pathway analyses. Because GO analysis is better suited
for larger gene lists, we also analyzed gene lists generated at a
slightly lower statistical stringency. Analysis at p o 0.05, Benja-
mini–Hochberg (FDR of 5%) identiﬁed 134, 252, and 185 NOD
altered genes at 2, 3, and 4 weeks, respectively (Tables S2, S3 and
S4, respectively). The topmost ranked major biological process of
these gene lists was metabolism (Table 5). Although common to all
3 ages, this functional category was most signiﬁcantly enriched at
2 weeks. Several biological processes unique to 3 weeks were also
identiﬁed, including biopolymer modiﬁcation, localization and
transport, and T cell activation. Under "molecular function",
hydrolase activity and binding were the common top ranked
categories. "Intracellular" was the most signiﬁcantly enriched
cellular component for all the 3 lists. Nucleus and cytoplasm/
endoplasmic reticulum were uniquely enriched at 2 and 3 weeks,
respectively. The immune system process ranked at the top of the
biological process at 4 weeks in the analysis of the gene list
generated at the higher stringency level (p o 0.005, Benjamini–
Hochberg; FDR of 0.5). Findings of the GO analyses were consistent
with those from our "manual" literature searches. We then
performed KEGG pathway analysis to identify well characterized
molecular pathways that were signiﬁcantly over-represented in
the gene lists of NOD altered genes. Results of the smaller and
larger gene lists of NOD altered genes were similar; only those of
the smaller lists are presented (Table 6). Consistent with the GO
analysis, the predominantly enriched category was metabolic
pathways, which still was most highly signiﬁcantly enriched at
2 weeks as compared to the other two ages. Five NOD altered
genes common to all 3 ages were identiﬁed in these
metabolic pathways: Enpp3 (ectonucleotide pyrophosphatase/
phosphodiesterase 3), Ndufs5 (NADH dehydrogenase (ubiquinone)
FeS protein 5), Galnt10 (UDP-N-acetyl-alpha-D-galactosamine:
polypeptide N-acetylgalactosaminyltransferase 10), Prim2 (DNA
primase, p58 subunit) and Gatm. These ﬁndings suggest that these
genes may contribute to the metabolic abnormalities that affect
the immune system and predispose NOD mice to autoimmune
diabetes. Overall, these data suggest that CD4 T-cells from NOD
mice already have a defect in metabolism (most prominent at
2 weeks), cellular activation and endoplasmic reticulum function
(both evident at 3 weeks) and T-cell/immune response (evident at
3–4 weeks) at the preinsulitis stage.
3.3. Transcriptional regulatory pathways of the CD4 T-cell NOD
altered genes
The 4 topmost signiﬁcantly enriched transcription factor bind-
ings sites (Table 7) were for androgen receptor (Ar), signiﬁcantly
enriched at 2 and 4 weeks; Interferon regulatory factor 1 (Irf1),
signiﬁcantly enriched at all 3 ages; and Interferon regulatory factor
7 (Irf7) and Interferon sensitive response elements (ISRE) both
signiﬁcantly enriched at 3 and 4 weeks. ISRE are present in the
promoters of interferon stimulated genes (ISGs), also known as
antiviral or innate immune response genes. All 4 binding sites
were most highly signiﬁcantly enriched at 4 weeks. Interestingly,
each putative transcription regulator correlated with a different
set of NOD altered genes at the various stages it was signiﬁcantly
enriched, including both age-common and age-speciﬁc NOD
altered genes. This suggests a dynamic (possibly coordinated)
regulation of gene expression. The promoter analysis data suggest
that expression of the NOD altered genes was signiﬁcantly more
likely to be regulated by Ar, Irf1, Irf7, and type I interferon than by
other transcription regulators.
3.4. Ingenuity Pathway Networks of the CD4 T-cell NOD altered
genes
In addition to the transcriptional regulatory pathway analysis,
we performed Ingenuity pathway analysis (IPA; 17,18) to gain
further insights into the genes/molecules that may play a role in
regulating the expression of the NOD CD4 T-cell altered genes and/
or molecular pathways. IPA analyses of the 3 "smaller" lists of NOD
altered genes (Tables 1–4) generated several networks each. The
major biological functions signiﬁcantly represented by the
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Table 1
Genes differentially expressed in CD4 T-cells from 2 week-old NOD mice.
Probe set ID Gene symbol Fold change Adjusted p-value Chromosome (Chr) T1D susceptibility region
Immune response
1418642_at (L) Lcp2 –9.65 0.00048 Chr11 
1457088_at (H) Pldn 5.48 0.00128 Chr2 Idd13
Apoptosis/cell proliferation
1440493_at (L) Galnt10 –37.09 0.000217 Chr11 
1457812_at (L) Trp53bp1 –30.33 0.000291 Chr2 Idd13
1438462_x_at (L) Khdrbs1 –7.42 0.000662 Chr4 Idd9/11
1417714_x_at (H) Hba-a1 5.36 0.0031 Chr11 
1449716_s_at (H) Nrd1 2.77 0.00321 Chr4 
1439650_at (L) Rtn4 –5.74 0.00296 Chr11 
1440358_at (H) Arhgef15 4.82 0.00184 Chr11 
1428361_x_at (L) Hba-a1 –4.11 0.00104 Chr11 
1444890_at (L) Mprip –4.08 0.00368 Chr11 
1449052_a_at (L) Dnmt3b –3.24 0.00048 Chr2 Idd13
1433681_x_at (L) Capn3 –2.30 0.00214 Chr2 Idd13
Transcription
1458094_at (L) Zfp407 –6.66 0.00224 Chr18 Idd21.1
1458274_at (H) Zfp69 3.06 0.00288 Chr4 
1446147_at (H) Rbm39 4.15 0.00129 Chr2 Idd13
Transport
1455735_at (H) Ap1s3 4.28 0.000512 Chr1 Idd5.4a/5.4
1417963_at (H) Pltp 3.00 0.00419 Chr2 
1420897_at (L) Snap23 –1.81 0.000668 Chr2 Idd13
Zinc-ion binding
1437432_a_at (L) Trim12a –769.41 2.45E-08 Chr7 Idd27
1443858_at (L) Trim/12c (Trim5) –238.91 3.05E-07 Chr7 Idd27
Protein/nucleic acid binding
1424454_at (H) Tmem87a 13.40 0.00114 Chr2 Idd13
1455863_at (L) Spata5l1 –5.40 0.00217 Chr2 
1419276_at (H) Enpp1 2.07 0.00105 Chr10 
1453065_at (H) Aldh5a1 1.78 0.00337 Chr13 
Other enzymes
1442424_at (L) Ctdspl2 –46.26 0.000831 Chr2 Idd13
1418035_a_at (L) Prim2 –11.25 5.55E-05 Chr1 Idd26
1423569_at (L) Gatm –7.41 0.000112 Chr2 Idd13
1453009_at (L) Cpm –6.18 0.00158 Chr10 
1416494_at (L) Ndufs5 –5.21 0.000538 Chr4 
1427943_at (H) Acyp2 2.75 4.07E-05 Chr11 
1427302_at (H) Enpp3 2.66 0.0027 Chr10 
1417826_at (L) Akr1e1 –6.52 0.000273 Chr13 
1455219_at (L) Slx1b –5.00 0.00184 Chr7 Not Assigned
1442466_a_at (L) Ppip5k1 –4.14 0.00211 Chr2 Idd13
1444377_at (L) Psmb2 –3.41 0.0028 Chr4 Idd11
1435129_at (H) Ptp4a2 2.37 0.00487 Chr4 Idd9/11
1454772_at (L) Snrnp200 –2.32 0.00189 Chr2 Idd13
1415878_at (L) Rrm1 –1.90 0.00407 Chr7 
1451998_at (L) Tasp1 –1.78 0.000499 Chr2 Idd13
Other (unknown transcripts are indicated below in the legend)
1444741_at (L) Dock2 –144.49 3.18E-06 Chr11 
1436061_at (L) Chaf1a –21.85 0.000538 Chr17 
1442824_at (L) Raly –13.69 0.000313 Chr2 Idd13
1452426_x_at (L) LOC433762 –12.00 0.000549 Chr4 
1452359_at (L) Rell1 –2.53 0.000662 Chr5 
1457822_at (L) Tmem131 –13.55 0.00438 Chr1 Idd26
1445214_at (L) Rex2 –9.26 0.000783 Chr4 Idd9.2
1456635_at (L) Sp110 –8.01 0.00156 Chr1 Idd5.4a/5.4
1428587_at (L) Tmem41b –4.36 0.000289 Chr7 Idd27
1424509_at (H) Cd177 4.03 0.00284 Chr7 
1435792_at (H) Csprs 3.86 0.00199 Chr1 Idd5.4a/5.4
1458684_at (H) Ss18 2.77 0.00407 Chr18 Idd21.3
1424721_at (L) Mfap3 –2.54 0.000895 Chr11 
1425331_at (L) Zfp106 –2.10 0.00183 Chr2 Idd13
Statistical analysis (1-way-ANOVA; p o 0.005, Benjamini–Hochberg) followed by hierarchical clustering identiﬁed 58 differentially expressed probe sets (representing 56
different genes) at 2 weeks; L and H, respectively, indicate lower or higher expression in NOD mice compared to control mice, NOR and C57BL/6. Two unknown transcripts
(both on Chr4) included: 9930104L06Rik (L) and 2510039O18Rik (L; Idd9.2). Fold change (FC) was calculated by ratio of means of expression in NOD mice versus controls.
Dashes indicate those genes are not located within a known T1D susceptibility region (Idd); all indicated Idds (except one, Idd5.4a/5.4) were identiﬁed as conferring
resistance to diabetes (http://www.t1dbase.org). Genes highlighted in bold font were differentially expressed at all 3 ages, 2, 3 and 4 weeks.
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Table 2
Genes differentially expressed in CD4 T-cells from 3 week-old NOD mice (continued in Table 3).
Probe set ID Gene symbol Fold change Adjusted p-value Chromosome (Chr) T1D susceptibility region
Immune response
1418642_at (L) Lcp2 –12.20 0.00339 Chr11 
1457088_at (H) Pldn 5.67 0.000481 Chr2 Idd13
1448550_at (L) Lbp –3.98 0.000176 Chr2 Idd13
1435529_at (L) Iﬁt1lb –2.91 0.00242 Chr19 
1460394_a_at (H) Inppl1 2.76 0.00318 Chr7 
1450783_at (L) Iﬁt1 –2.73 0.00395 Chr19 
1424775_at (L) Oas1a –2.20 0.00115 Chr5 
1418580_at (L) Rtp4 –2.10 0.00317 Chr16 
1448940_at (L) Trim21 –2.03 0.00399 Chr7 Idd27
1435560_at (L) Itgal –1.84 0.00242 Chr7 Not Assigned
1452956_a_at (L) Iﬁ27 –1.74 0.00484 Chr6
Apoptosis/cell proliferation
1457812_at (L) Trp53bp1 –16.30 0.000964 Chr2 Idd13
1440493_at (L) Galnt10 –11.41 0.000748 Chr11 
1417714_x_at (H) Hba-a1 10.69 0.000156 Chr11 
1438462_x_at (L) Khdrbs1 –5.59 0.000211 Chr4 Idd9/11
1449716_s_at (H) Nrd1 2.36 0.00133 Chr4 
1452677_at (H) Pnpt1 13.80 0.0012 Chr11 
1440319_at (L) Mef2a –13.53 0.00227 Chr7 
1444890_at (L) Mprip –9.37 0.00439 Chr11 
1439650_at (L) Rtn4 –5.24 0.00318 Chr11 
1433681_x_at (L) Capn3 –2.89 0.000442 Chr2 Idd13
1428819_at (L) Mapre1 –2.78 0.00242 Chr2 Idd13
1449052_a_at (L) Dnmt3b –2.77 1.06E-05 Chr2 Idd13
1436647_at (H) Ttbk2 2.69 0.00254 Chr2 Idd13
1419269_at (H) Dut 2.54 0.0016 Chr2 Idd13
1444500_at (L) Ahsa1 –2.48 0.0042 Chr12 
1436025_at (H) Ccdc88a 2.40 0.000697 Chr11 
1441937_s_at (L) Pink1 –2.11 0.00159 Chr4 
1448184_at (L) Fkbp1a –1.94 0.00449 Chr2 Idd13
1422808_s_at (L) Dock2 –1.84 0.000999 Chr11 
1457813_at (H) Trp53bp1 1.62 0.0044 Chr2 Idd13
1448027_at (L) Ncoa3 –1.47 0.00277 Chr2 
1419562_at (L) Birc6 –1.31 0.00393 Chr17 
Transcription
1458094_at (L) Zfp407 –8.70 0.000878 Chr18 Idd21.1
1458274_at (H) Zfp69 3.25 0.00264 Chr4 
1449592_at (H) Tcf15 10.64 0.000988 Chr2 Idd13
1459026_at (L) Snw1 –10.00 0.00152 Chr12
1417961_a_at (L) Trim30 –7.39 2.84E-05 Chr7 Idd27
1445214_at (L) Zfp715 –4.30 0.000612 Chr7 
1447703_x_at (L) Zfp593 –4.09 5.47E-05 Chr4 
1442356_at (L) Max –2.24 0.00491 Chr12 
1426765_at (L) Commd7 –2.09 0.000466 Chr2 Idd13
1436416_x_at (L) Fxc1 –1.81 6.23E-05 Chr7 Idd27
1450350_a_at (L) Jdp2 –1.39 0.00475 Chr12 
Transporters
1460617_s_at (L) Rab6b –15.69 0.000612 Chr9 
1458426_at (L) Kif1b –3.72 0.000704 Chr4 Idd9.2
1455735_at (H) Ap1s3 3.09 0.00386 Chr1 Idd5.4a/5.4
1424615_at (L) Pgap2 –2.18 0.0019 Chr7 Idd27
1424211_at (H) Slc25a33 1.83 0.0012 Chr4 
Zinc-ion binding
1437432_a_at (L) Trim12a –252.63 1.20E-08 Chr7 Idd27
1443858_at (L) Trim12c (Trim5) –140.08 5.39E-07 Chr7 Idd27
1435665_at (L) Trim30d –3.16 0.00227 Chr7 Idd27
Statistical analysis (1-way-ANOVA; p o 0.005, Benjamini–Hochberg) followed by hierarchical clustering identiﬁed 115 differentially expressed probe sets (representing 107
different genes) at 3 weeks; L and H, respectively, indicate lower or higher expression in NOD mice compared to control mice, NOR and C57BL/6. This table shows a partial list
of the genes; the remaining genes are shown in Table 3. Fold change (FC) was calculated by ratio of means of expression in NOD mice versus controls. Dashes indicate those
genes are not located within a known T1D susceptibility region (Idd); all indicated Idds (except one, Idd5.4a/5.4) were identiﬁed as conferring resistance to diabetes
(http://www.t1dbase.org). Genes highlighted in bold font were differentially expressed at all 3 ages, 2, 3 and 4 weeks.
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networks included cell cycle, cellular growth/proliferation, and cell
death at 2 weeks; molecular transport, cell-to-cell signaling and
interaction, and immune system development and function at
3 weeks; and antiviral (innate immune) function and immune
response at 4 weeks. The merged networks for each dataset
clustered around several central genes (Figs. 2–4). To facilitate an
objective comparison between networks and to gain further
insights, we ranked the central genes according to the total
number of connections linked to each one of them – the more
the number of connections, the higher the rank. The top 15 central
genes and their directly linked focus genes are shown in Table 8.
This analysis revealed that seven central genes were common to
all 3 ages, including transcription factors, hepatic nuclear factor 4,
alpha (Hnf4a) and transformation related protein 53 (Trp53); anti-
apoptotic factor, BCL2-like 1 (Bcl2l1); cytokines, interferon gamma
(Ifng), interleukin 4 (Il4) and interleukin 15 (IL15); and the pro-
inﬂammatory factor, prostaglandin E2. The pro-inﬂammatory
cytokine, interleukin 6 (Il6) was common to ages 2 and 4 weeks.
Other genes were unique to the respective age groups, e.g. to
2 weeks: transcription factors, myelocytomatosis oncogene (Myc),
Jun oncogene (Jun), and amyloid beta (A4) precursor protein
(App); to 3 weeks: the pro-inﬂammatory cytokine, tumor necrosis
factor (Tnf), the anti-inﬂammatory cytokine, Tgfb1 (transforming
growth factor, beta 1), and cell signaling molecules NFκB, ERK,
p38MAPK, and insulin-like growth factor 1 (Igf1); and to 4 weeks:
cytokines, interferon alpha and IL12 (interleukin 12), the tran-
scription factor signal transducer and activator of transcription 4
(Stat4), and Rous sarcoma oncogene (Src). Interestingly, the central
genes Bcl2l1 and Src are also located within Idd13. The biological
processes associated with the central genes that were common to
all 3 ages included apoptosis/cellular proliferation, Th1–Th2
balance, cytokine signaling, and inﬂammation. Those associated
with the age-speciﬁc central genes included apoptosis/cell prolif-
eration (at 2 weeks), cell signaling/cellular activation and inﬂam-
mation (at 3 weeks), and innate immunity/link to adaptive
immune response (at 4 weeks). Similar to the promoter analysis,
each of the common central genes was connected to a different set
of focus genes at the various ages, consisting of both age-common
and age-speciﬁc genes, again suggesting a dynamic coordinated
regulation of the molecular processes over time. These data
suggest that abnormalities in apoptosis/cellular proliferation pre-
dominate at 2 weeks of age, while those in cell signaling/cellular
activation and inﬂammation predominate at 3 weeks of age.
Abnormalities in the innate immune response and its link to
adaptive immunity predominate at 4 weeks of age.
4. Discussion
Type 1 diabetes is a multigenic disease whose study would
beneﬁt from a non-targeted approach to simultaneously identify
the genes/pathways that are involved in the disease process [20].
Here, we employed a novel 3-way analysis where NOD was
compared to two diabetes-resistant strains, C57BL/6 and NOR.
Comparison with NOR mice (a strain that is 88% identical to NOD
mice, including sharing the diabetogenic H2g7 MHC haplotype)
afforded us the ability to identify gene expression changes (and
their associated molecular networks) that might contribute to T1D
susceptibility in NOD or, conversely, resistance in NOR mice in the
context of a permissive MHC haplotype. This study conﬁrmed as
well as advanced our recently published studies on unfractionated
spleen leukocytes [25] in that, in addition to using the NOR control
Fig. 1. Hierarchical clusters of genes whose expression was altered in CD4 T-cells. 362 (A), 982 (B) and 581 (C) genes were differentially expressed between strains at 2, 3,
and 4 weeks of age, respectively. The lists were identiﬁed by a one-way ANOVA of 31,000 ﬁltered probe sets at p o 0.005, with Benjamini–Hochberg multiple test
correction. A total of 58, 115, and 65 probe sets were differentially expressed in NOD relative to both controls (NOR and C57BL/6) at 2-, 3- and 4-weeks, respectively; clusters
of these NOD altered genes are indicated by arrows. The color intensity of the rectangles representing each gene for each sample (n ¼ 5 for each strain/age, except NOD
2 week, where n ¼ 4) indicates the degree of increase (red) or decrease (blue) of the gene expression signal relative to the mean signal intensity (yellow).
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strain, we focused on a speciﬁc leukocyte subset (CD4 T-cells) and
included an additional time point (3 weeks of age), all of which
allowed us to identify novel altered pathways.
NOR mice remain diabetes-free due to resistance alleles within
the 12% portion of their genome derived from BKs [4,17,29,30].
These BKs-derived genomic regions are present on chromosomes
1, 2, 4, 5, 7, 10, 11, 12, 14 and 18 [17,29,30]. Unsurprisingly, virtually
all the NOD altered genes identiﬁed in the current study are
located on these chromosomes (Tables 1–4). Strikingly, a large
number of these genes lie within known diabetes susceptibility
regions (Tables 1–4). Linkage/congenic studies have provided
evidence for the presence of NOR resistance genes on Chr1
(Idd5.2), Chr2 (Idd13) and Chr4 (Idd9/11), and potentially on
Chr11 [15–17,30]. However, several studies also suggest that genes
Table 3
Genes differentially expressed in CD4 T-cells from 3 week-old NOD mice (continued from Table 2).
Probe set ID Gene symbol Fold change Adjusted p-value Chromosome (Chr) T1D susceptibility region
Protein/nucleic acid binding
1424454_at (H) Tmem87a 13.41 0.00264 Chr2 Idd13
1455863_at (L) Spata5l1 –10.62 7.71E-06 Chr2 
1459957_at (H) Tnrc6a 5.53 0.000595 Chr7 Not Assigned
1429247_at (L) Anxa6 –4.00 0.000999 Chr11 Idd4.3
1458684_at (H) Ss18 2.56 0.00101 Chr18 Idd21.3
1419276_at (H) Enpp1 2.48 0.000575 Chr10 
1416559_at (L) Rrp8 –2.32 0.00226 Chr7 Idd27
1440416_at (H) Usp46 2.07 0.00153 Chr5 
1429337_at (L) Tmem87b –1.52 0.00159 Chr2 Idd13
1428308_at (L) Pdrg1 –1.36 0.00361 Chr2 Idd13
Other enzymes
1442424_at (L) Ctdspl2 –53.79 0.000129 Chr2 Idd13
1453009_at (L) Cpm –16.36 0.000671 Chr10 
1427302_at (H) Enpp3 3.45 0.0016 Chr10 
1418035_a_at (L) Prim2 –10.26 1.11E-05 Chr1 Idd26
1423569_at (L) Gatm –8.19 7.47E-05 Chr2 Idd13
1416494_at (L) Ndufs5 –6.65 1.44E-05 Chr4 
1427943_at (H) Acyp2 3.91 0.000117 Chr11 
1444377_at (L) Psmb2 –2.86 0.00325 Chr4 Idd11
1449862_a_at (H) Pi4k2b 2.85 0.00324 Chr5 
1451277_at (L) Zadh2 –2.50 0.000108 Chr18 Idd21.1
1435129_at (H) Ptp4a2 2.47 0.0033 Chr4 Idd9/11
1420613_at (L) Ptp4a2 –2.22 0.000306 Chr4 Idd9/11
1455075_at (L) Pigv –2.15 0.00133 Chr4 
1419125_at (L) Ptpn18 –1.99 0.00395 Chr1 Idd26
1453343_s_at (H) Vrk2 1.97 0.00454 Chr11 
Other
1444741_at (L) Dock2 –46.41 2.48E-05 Chr11 
1436061_at (L) Chaf1a –24.94 0.000216 Chr17 
1442824_at (L) Raly –23.88 0.000306 Chr2 Idd13
1452426_x_at (L) LOC433762 –22.39 0.00114 Chr4 
1452359_at (L) Rell1 –2.84 0.00152 Chr5 
1444878_at (L) Nf1 –10.91 0.000999 Chr11 
1428318_at (H) Smgc 7.02 0.0019 Chr15 
1424133_at (H) Tmem98 7.32 4.09E-05 Chr11 
1432391_at (L) Ccdc21 –5.10 0.000648 Chr4 
1434112_at (L) Lphn2 –3.65 0.00201 Chr3 
1428587_at (L) Tmem41b –3.57 1.06E-05 Chr7 Idd27
1456685_at (L) HMP19/Nsg2 –3.58 0.000655 Chr11 
1451477_at (H) Znf41-ps 2.90 2.66E-05 Chr4 Idd9.2
1444714_at (L) Dcdc2b –2.77 0.00166 Chr4 
1453465_x_at (L) Ppp1r14c –2.30 0.00159 Chr10 
1431259_at (H) Adal 2.28 0.0044 Chr2 Idd13
1424721_at (L) Mfap3 –1.93 0.00143 Chr11 
1445186_at (H) Stc2 1.78 0.00367 Chr11 
1416935_at (L) Trpv2 –1.61 0.00289 Chr11 
Unknown
1428604_at (H) 2610305D13Rik 28.19 0.00125 Chr4 Idd9.2
1434550_at (L) 3830406C13Rik –16.63 0.00157 Chr14 
1436388_a_at (L) 3830406C13Rik –10.85 0.0025 Chr14 
1440214_at (L) A630001G21Rik –8.76 0.0044 Chr1 Idd5.4a/5.4
1429203_at (H) 2410076I21Rik 3.10 5.59E-05 Chr9 Idd2
1438646_x_at (L) 2510039O18Rik –2.69 0.00214 Chr4 Idd9.2
1458419_at (L) E130215H24Rik –2.11 0.00254 Chr2 Idd13
Statistical analysis (1-way-ANOVA; p o 0.005, Benjamini–Hochberg) followed by hierarchical clustering identiﬁed 115 differentially expressed probe sets (representing
107 different genes) at 3 weeks; L and H, respectively, indicate lower or higher expression in NOD mice compared to control mice, NOR and C57BL/6. This table
shows a continuation of the gene list from Table 2. Fold change (FC) was calculated by ratio of means of expression in NOD mice versus controls. Dashes indicate those
genes are not located within a known T1D susceptibility region (Idd); all indicated Idds (except one, Idd5.4a/5.4) were identiﬁed as conferring resistance to diabetes
(http://www.t1dbase.org). Genes highlighted in bold font were differentially expressed at all 3 ages, 2, 3 and 4 weeks.
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Table 4
Genes differentially expressed in CD4 T-cells from 4 week-old NOD mice.
Probe set ID Gene symbol Fold change Adjusted p-value Chromosome (Chr) T1D susceptibility region
Immune response
1418642_at (L) Lcp2 –20.53 7.58E-06 Chr11 
1457088_at (H) Pldn 4.60 0.0027 Chr2 Idd13
1421571_a_at (L) Ly6c1 –9.30 8.63E-07 Chr15 
1435529_at (L) Iﬁt1 –3.69 9.11E-06 Chr19 
1419599_s_at (L) Ms4a6d –3.46 1.85E-05 Chr19 
1436058_at (L) Rsad2 –2.913 0.00244 Chr12 
1450783_at (L) Iﬁt1l –2.58 0.00101 Chr19 
1449025_at (L) Iﬁt3 –2.39 0.00306 Chr19 
1424775_at (L) Oas1a –2.33 0.0015 Chr5 
1422903_at (L) Ly86 –2.26 0.00158 Chr13 Idd14
1418580_at (L) Rtp4 –2.23 0.000429 Chr16 
Apoptosis/cell proliferation
1457812_at (L) Trp53bp1 –20.92 0.00426 Chr2 Idd13
1440493_at (L) Galnt10 –10.93 0.00256 Chr11 
1438462_x_at (L) Khdrbs1 –9.83 2.51E-06 Chr4 Idd9/11
1417714_x_at (H) Hba-a1 5.67 0.00182 Chr11 
1449716_s_at (H) Nrd1 2.62 1.50E-05 Chr4 
1428371_at (H) Ttbk2 1.99 0.0025 Chr2 Idd13
Transcription
1458094_at (L) Zfp407 –5.59 0.0015 Chr18 Idd21.1
1458274_at (H) Zfp69 2.97 0.00361 Chr4 
1459026_at (L) Snw1 –5.40 6.75E-05 Chr12 
1447703_x_at (L) Zfp593 –4.20 0.00209 Chr4 
1417961_a_at (L) Trim30 –3.58 0.000703 Chr7 Idd27
1421519_a_at (L) Zfp120 –2.30 0.000974 Chr2 Idd13
Transporters
1434914_at (L) Rab6b –36.11 0.000308 Chr9 
1458426_at (L) Kif1b –3.49 0.00345 Chr4 Idd9.2
1421098_at (L) Stap1 –1.39 0.00361 Chr5 
Zinc-ion binding
1437432_a_at (L) Trim12a –186.81 2.35E-07 Chr7 Idd27
1443858_at (L) Trim12c (Trim5) –664.23 1.15E-08 Chr7 Idd27
1435665_at (L) Trim30d –3.73 0.000726 Chr7 Idd27
1421550_a_at (L) Trim34 –2.46 0.00119 Chr7 Idd27
1451277_at (L) Zadh2 –2.29 0.00237 Chr18 Idd21.1
1434193_at (L) Zmym6 –1.60 0.000597 Chr4 Idd11
Protein/nucleic acid binding
1424454_at (H) Tmem87a 9.56 0.00354 Chr2 Idd13
1455863_at (L) Spata5l1 –7.28 0.000253 Chr2 
1444714_at (L) Dcdc2b –2.90 0.00328 Chr4 
1431231_at (L) Hist1h3f –2.33 0.0028 Chr13 
1435312_at (L) Paqr7 –2.08 0.00243 Chr4 
Other enzymes
1442424_at (L) Ctdspl2 –36.64 0.000789 Chr2 Idd13
1453009_at (L) Cpm –12.24 6.21E-06 Chr10 
1418035_a_at (L) Prim2 –7.69 4.78E-05 Chr1 Idd26
1423569_at (L) Gatm –5.45 0.00467 Chr2 Idd13
1416494_at (L) Ndufs5 –5.42 9.99E-06 Chr4 
1427302_at (H) Enpp3 3.32 0.00172 Chr10 
1427943_at (H) Acyp2 2.53 0.000285 Chr11 
1442466_a_at (L) Ppip5k1 –2.84 0.000837 Chr2 Idd13
1455075_at (L) Pigv –2.56 0.00188 Chr4
1451998_at (L) Tasp1 –2.53 0.0044 Chr2 Idd13
1433977_at (L) Hs3st3b1 –2.48 0.00247 Chr11 
Other (unknown transcripts are indicated below in the legend)
1444741_at (L) Dock2 –31.19 0.000307 Chr11 
1436061_at (L) Chaf1a –13.09 0.000734 Chr17 
1452426_x_at (L) LOC433762 –13.07 1.08E-05 Chr4 
1452359_at (L) Rell1 –2.50 0.00113 Chr5 
1442824_at (L) Raly –12.31 0.000974 Chr2 Idd13
1442494_at (L) Ubr2 –11.47 6.75E-05 Chr17 
1456635_at (L) Sp110 –8.90 0.00437 Chr1 Idd5.4a/5.4
1456685_at (L) Nsg2 –2.96 0.0021 Chr11 
Statistical analysis (1-way-ANOVA; p o 0.005, Benjamini–Hochberg) followed by hierarchical clustering identiﬁed 65 differentially expressed probe sets (representing 60
different genes) at 4 weeks; L and H, respectively, indicate lower or higher expression in NOD mice compared to control mice, NOR and C57BL/6. Fold change (FC) was
calculated by ratio of means of expression in NOD mice versus controls. Dashes indicate those genes are not located within a known T1D susceptibility region (Idd); all
indicated Idds (except one, Idd5.4a/5.4) were identiﬁed as conferring resistance to diabetes (http://www.t1dbase.org). Two unknown transcripts included: BE373131 (L;
Chr19) and A230098N10Rik (H; Chr5). Genes highlighted in bold font were differentially expressed at all 3 ages, 2, 3 and 4 weeks.
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in other genetic regions distinguishing NOR from NOD may also
act interactively with genes in these loci to protect NOR mice from
autoimmune diabetes [5,10,30], thus providing further support for
the signiﬁcance of investigations at the whole cellular or mole-
cular systems level. In further support for whole molecular
systems studies, F2 segregation studies and subsequent subcon-
genic analyses have found that Idd13 (Chr2) and Idd9/11 (Chr4)
each consist of multiple genes that contribute to NOR resistance
[10,16,17,30]. Our study revealed that a total of 26 different NOD
CD4 T-cell altered genes lie within Idd13, including 6 (Bloc1s6,
Trp53bp1, Tmem87a, Ctdspl2, Gatm and Raly) that were common
to the 3 ages studied (Tables 1–4). Interestingly, two central genes
in the IPA networks, Bcl2l1 and Src (Table 8), also lie within this
locus. Bcl2l1 is linked to 3 genes, Galnt10, Rtn4 (reticulon 4) and
Pnpt1 (polyribonucleotide nucleotidyltransferase 1) that are
located on Chr11, while Src is linked to 2 genes, Paqr7 (progestin
and adipoQ receptor family member VII) and Khdrbs1 that are
located on Chr4. Of note, Khdrbs1 is located within a known Idd9/
11 (discussed below) while the 3 Bcl2l1 linked genes and Paqr7 are
not located within a known Idd, and thus may deﬁne novel T1D
susceptibility loci. These results attest to the utility of molecular
network analyses in identifying novel Idds or genes not in known
Table 5
Enriched Gene ontology categories for the list of CD4 T-cell NOD altered genes.
GO category 2 wk (134 genes) 3 wk (252 genes) 4 wk (185 genes)
No. of genes in
category
p-value No. of genes in
category
p-value No. of genes in
category
p-value
Biological process
Cellular metabolism 53 4.24e-5 88 1.13e-3 67 1.88e-3
Primary metabolism 52 2.82e-5 86 7.06e-4  
Nucleobase, nucleoside,
nucleotide and nucleic
acid metabolism
28 2.02e-3   35 8.88e-3
Biopolymer modiﬁcation   25 6.53e-3  
Localization   43 1.13e-3  
Cytoskeletal organization
and biogenesis
  11 9.07e-3  
Transport   36 7.49e-3  
Intracellular transport   16 1.64e-3  
Secretion   8 5.70e-3  
Leukocyte activation   6 8.80e-3  
T cell activation   5 3.17e-3  
Regulation of hydrolase
activity
  4 8.07e-3  
Molecular function
Catalytic activity     60 2.89e-3
Hydrolase activity 22 2.84e-3 40 7.88e-4 30 2.30e-3
Hydrolase activity, acting
on ester bonds
10 3.01e-3 15 6.23e-3 14 8.65e-4
Phosphoric ester
hydrolase activity
7 1.32e-3 10 1.99e-3 10 1.75e-4
Hydrolase activity, acting
on acid anhydrides
  16 4.48e-4  
Pyrophosphatase activity   15 1.12e-3  
GTPase activity   6 3.49e-3  
Nucleotidyltransferase
activity
  5 7.76e-3 6 2.82e-4
Inositol or
phosphatidylinositol
phosphatase activity
    4 1.63e-4
Binding   140 3.87e-5 99 4.64e-3
Metal ion binding   55 2.85e-3 43 2.02e-3
Protein binding   69 1.89e-3
Cation binding 28 8.09e-3 39 6.74e-3
Transition metal ion
binding
26 2.49e-3 34 4.44e-4
Zinc ion binding 24 6.04e-5 29 5.59e-4
Nucleic acid binding 28 4.70e-3
Cellular component
Intracellular 65 2.81e-5 113 2.35e-7 79 5.64e-4
Intracellular organelle 53 1.22e-3 88 9.33e-4  
Intracellular membrane-
bound organelle
48 1.39e-3 80 6.71e-4  
Nucleus 33 8.06e-3    
Cytoplasm   58 1.38e-4  
Endoplasmic reticulum   15 1.72e-3  
One-way ANOVA (po0.05, Benjamini–Hochberg) of mRNA expression data followed by hierarchical clustering identiﬁed 134, 252, and 185 different genes at 2, 3, and
4 weeks, respectively, whose expressionwas altered in CD4 T-cells from NODmice compared to two control strains (NOR and C57BL/6). These lists of NOD altered genes were
analyzed in WebGestalt (http://bioinfo.vanderbilt.edu/webgestalt) using the hypergeometric test (p o 0.01). Categories represented by Z 4 genes are shown. Dashes indicate
that the corresponding categories were not signiﬁcantly enriched at the respective ages. Categories indicated in bold font were common to all 3 age groups.
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Idds that could act interactively upstream or downstream of Idd
regions to contribute to diabetes development. The role of these
genes needs to be conﬁrmed in future studies. Several groups have
determined that resistance genes in Idd9/11 (Chr4) regulate the
diabetogenic activity of CD4 T-cells [5,10,18,19]. Interestingly, two
of the NOD altered genes (Khdrbs1 and Ptp4a2) lie within Idd9/11,
Table 6
Enriched KEGG pathways for the list of CD4 T-cell NOD altered genes.
KEGG pathway Adjusted p-value No. of genes Genes in the pathway
2 wk
Metabolic pathways 1.01e-5 9 Enpp3, Ndufs5, Galnt10, Prim2, Gatm, Dnmt3b, Akr1e1, Enpp1, Rrm1
Purine metabolism 5.22e-5 4 Enpp3, Prim2, Enpp1, Rrm1
Pantothenate and CoA biosynthesis 0.0001 2 Enpp3, Enpp1
Riboﬂavin metabolism 0.0001 2 Enpp3, Enpp1
Nicotinate and nicotinamide metabolism 0.0003 2 Enpp3, Enpp1
Starch and sucrose metabolism 0.0008 2 Enpp3, Enpp1
Pyrimidine metabolism 0.0039 2 Prim2, Rrm1
3 wk
Metabolic pathways 0.0005 10 Enpp3, Ndufs5, Galnt10, Prim2, Gatm, Inppl1, Dnmt3b, Akr1e1, Dut, Enpp1
Riboﬂavin metabolism 0.0008 2 Enpp3, Enpp1
Purine metabolism 0.0008 4 Enpp3, Prim2, Enpp1
Pantothenate and CoA biosynthesis 0.0008 2 Enpp3, Enpp1
Pyrimidine metabolism 0.0013 3 Prim2, Pnpt1, Dut
Nicotinate and nicotinamide metabolism 0.0008 2 Enpp3, Enpp1
Spliceosome 0.0029 3 Crnkl1, Srnp200, Snw1
Starch and sucrose metabolism 0.0031 2 Enpp3, Enpp1
4 wk
Metabolic pathways 0.0002 7 Enpp3, Ndufs5, Galnt10, Prim2, Gatm, Pigv, Mdh1
Pyruvate metabolism 0.0008 2 Acyp2, Mdh1
One-way ANOVA (p o 0.005, Benjamini–Hochberg) of mRNA expression data followed by hierarchical clustering identiﬁed 58, 115, and 65 probe sets at 2, 3 and 4 weeks,
respectively, whose expression was altered in CD4 T-cells from NODmice compared to two control strains (NOR and C57BL/6). The lists of differentially expressed genes were
analyzed in WebGestalt (http://bioinfo.vanderbilt.edu/webgestalt) for enriched KEGG pathways using the hypergeometric test (p o 0.01, Benjamini–Hochberg). Pathways
represented by Z2 genes are shown. Pathways or genes indicated in bold font were common to the 3 age groups.
Table 7
Transcription factor binding sites enriched in the promoters of CD4 T-cell NOD altered genes.
Transcription factor binding sites p-value No. of genes Gene names
2 wk
Ar 0.008 9 Enpp3, Trim34, Nrd1, Rell1, Hisppd2a, Rrm1, Sp140,
Trib3, A530032D15Rik
Irf1 0.015 11 Galnt10, Trim 34, Khdrbs1, Pldn, Tmem87a,
Trp53bp1, Enpp1, Mfap3, Psmb2, Rtn4, Snrnp200
3 wk
Irf1 3.74E-04 21 Galnt10, Trim34, Khdrbs1, Pldn, Tmem87a,
Trp53bp1, Trim21, Ahsa1, Capn3, Enpp1, Iﬁ27l1, Iﬁt1,
Mfap3, Pi4k2b, Psmb2, Ptpn18, Rtn4, Snrp200,
Tnrc6a, 1700029I01Rik, 2510039O18Rik
Irf7 0.002 17 Khdrbs1, Tmem87a, Zfp69, Trim21, Trim30, Anxa6,
Hisppd2a, Iﬁ27l1, Iﬁt1, Kif1b, Nsg2, Pdrg1, Pi4k2b,
Pnpt1, Zadh2, AI451617, 4930402H24Rik
ISRE 4.48E-04 17 Enpp3, Ndufs5, Trim12, Trim34, Khdrbs1, Zfp69,
Trim21, Trim30, Dyx1c1, Iﬁ27l1, Iﬁt1, Pi4k2b, Pldn,
Pnpt1, Snrp200, Tnrc6a, AI451617
4 wk
Ar 6.73E-04 11 Enpp3, Trim34, Nrd1, Rell1, Hisppd2a, Ly6c1, Ly86,
Oas1a, Sp140, Tasp1, A530032D15Rik
Irf1 8.13E-05 15 Galnt10, Trim34, Khdrbs1, Pldn, Tmem87a,
Trp53bp1, Iﬁt1, Iﬁt3, Ly86, Oas1a, Pigv, Rsad2, Rtp4,
Stap1, Zfp120
Irf7 2.50E-06 15 Khdrbs1, Tmem87a, Zfp69, Trim30, Hisppd2a, Iﬁt1,
Iﬁt3, Kif1b, Nsg2, Oas1a, Rsad2, Rtp4, Stap1, Zadh2,
AI451617
ISRE 5.58E-08 16 Enpp3, Ndufs5, Trim12, Trim34, Khdrbs1, Zfp69,
Trim30, Iﬁt1, Iﬁt3, Ly86, Oas1a, Pldn, Rsad2, Rtp4,
Zmym6, AI451617
One-way ANOVA (p o 0.005, Benjamini–Hochberg) of mRNA expression data followed by hierarchical clustering identiﬁed 58, 115, and 65 probe sets at 2, 3 and 4 weeks,
respectively, whose expression was altered in CD4 T-cells from NODmice compared to two control strains (NOR and C57BL/6). The lists of differentially expressed genes were
analyzed for enriched transcription factor binding sites in their promoters by using the PRIMA software of the EXPANDER suite (p o 0.05). Binding sites or genes indicated in
bold font were common to the 3 age groups. ISRE – interferon sensitive response elements.
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with Khdrbs1 (an adaptor protein involved in signal transduction
cascades of several receptor systems, including T-cell signaling)
being common to all 3 ages. In support of possible involvement of
interaction of genes on several genetic regions in suppressing the
diabetogenic activity of NOR CD4 T-cells, Chen et al. [5] reported
that CD4 T-cells from NOR mice were somewhat more protective
against diabetes than CD4 T-cells from NOD mice congenic for just
the NOR-derived Idd9/11. Our study provides support suggesting
that resistance genes within Idd13 (and their downstream genes)
may act interactively with those in Idd9/11 (and possibly in
unidentiﬁed Idd on Chr11) to regulate the diabetogenic activity
of CD4 T-cells.
In addition to the NOD CD4 T-cell altered genes discussed
above, several other altered genes also lie within Idds (Tables 1–4).
All (except Idd5.4a/5.4) have been identiﬁed as conferring resis-
tance to diabetes (http://www.t1dbase.org). An interesting family
of genes highlighted is the tripartite-motif (Trim) family. Com-
pared to the leukocyte study, the current study expanded the list
of Trim family members. These genes, whose expression was
repressed in NOD mice, with that of Trim5/12c and 12a virtually
undetectable, all lie within Idd27 on Chr7. Trim proteins, which
bear several domains, including three zinc-binding domains,
constitute a family of 60 molecules with diverse biological
functions, including regulation of inﬂammation and innate immu-
nity [31,32]. The order of the domains is conserved throughout
evolution supporting a common molecular property for these
proteins. We propose that one (or several) of the Trim family
members identiﬁed in our studies may play an important role in
immune cells in initiation of autoimmune diabetes. To this end,
Trim21, a gene that for a long time has been implicated in human
autoimmune diseases Sjögren’s syndrome and systemic lupus
erythematosus, in which patients exhibit Trim21 autoreactivity
[33], has been reported recently to regulate the innate immune
response to intracellular dsDNA [34]. Another Trim (Trim28) has
also been reported recently to be involved in the global regulation
of CD4 T-cells [35]. Mice with a conditional T cell-speciﬁc deletion
of Trim28 had a spontaneous autoimmune phenotype character-
ized by mononuclear tissue inﬁltration and altered cytokine
balance leading to nonfunctional T regulatory cells (Tregs).
Thus, the present study provides new insights into the genes/
pathways in CD4 T-cells that collectively might play a role in
diabetes development – resistance in NOR mice or susceptibility in
NOD mice. The BCL2L1 pathway and the genes within Idd13, Idd9/
11 and Idd27 that are altered at all 3 ages (Pldn, Trp53bp1,
Tmem87a, Ctdspl2, Gatm, Raly, Khdrbs1, and Trim12a and Trim5/
12c) make particularly interesting candidate genes/pathways as
they most likely represent basic genetic defects in the NOD mouse.
While our study has highlighted prime candidate genes, future
studies will conﬁrm which of the NOD altered genes and/or their
interacting partners or regulators act interactively to effect the
diabetogenic activity of NOD CD4 T-cells. In our lab, we are
investigating the genetic loci underlying the expression of the
altered CD4 T-cell molecular network to deﬁne key regulatory loci.
The majority of the CD4 T-cell NOD altered genes were
repressed, similar to the results of the spleen leukocyte study
[25] and supported by many other studies in both mice and
humans [36–42]. Kodama et al. [36] reported global repression
of genes in various tissues of NOD mice (including spleen cells) in
comparison to NOD.B10 controls, a strain in which the NOD MHC
haplotype is replaced with that from the nondiabetic B10 mice.
Liston et al. [37] also found a global dampening in gene expression
in NOD thymocytes of the genes involved in T cell negative
Fig. 2. Molecular network generated by ingenuity pathway analysis (IPA) from the dataset of 2 week-old mice. The merged network was generated from the list of genes
differentially expressed in CD4 T-cells from 2-week old NOD mice compared to both control strains (NOR and C57BL/6). The list was selected from the hierarchical cluster of
362 genes that had highly signiﬁcant (p o 0.005, Benjamini–Hochberg) expression differences between strains at 2 weeks of age. The genes derived from our uploaded gene
list (known as focus genes) are represented by gray icons while genes (or endogenous chemicals) derived from the IPA knowledge base that could be algorithmically
connected to the focus genes are represented by white icons. Different shapes of the symbols represent the different classes of genes/molecules, e.g. squares ¼ cytokines/
growth factors; ovals ¼ transcription factors, etc.
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Fig. 3. Molecular network generated by ingenuity pathway analysis (IPA) from the dataset of 3 week-old mice. The merged network was generated from the list of genes
differentially expressed in CD4 T-cells from 3-week old NOD mice compared to both control strains (NOR and C57BL/6). The list was selected from the hierarchical cluster of
982 genes that had highly signiﬁcant (p o 0.005, Benjamini–Hochberg) expression differences between strains at 3 weeks of age. The genes derived from our uploaded gene
list (known as focus genes) are represented by gray icons while genes (or endogenous chemicals) derived from the IPA knowledge base that could be algorithmically
connected to the focus genes are represented by white icons. Different shapes of the symbols represent the different classes of genes/molecules, e.g. squares ¼ cytokines/
growth factors; ovals ¼ transcription factors, etc.
Fig. 4. Molecular network generated by ingenuity pathway analysis (IPA) from the dataset of 4 week-old mice. The merged network was generated from the list of genes
differentially expressed in CD4 T-cells from 4-week old NOD mice compared to both control strains (NOR and C57BL/6). The list was selected from the hierarchical cluster of
581 genes that had highly signiﬁcant (p o 0.005, Benjamini–Hochberg) expression differences between strains at 4 weeks of age. The genes derived from our uploaded gene
list (known as focus genes) are represented by gray icons while genes (or endogenous chemicals) derived from the IPA knowledge base that could be algorithmically
connected to the focus genes are represented by white icons. Different shapes of the symbols represent the different classes of genes/molecules, e.g. squares ¼ cytokines/
growth factors; ovals ¼ transcription factors, etc..
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selection. They identiﬁed several differentially expressed type
1 diabetes candidate genes, among them four genes (Ly6c, Prim2,
Trim12, and Trim30) whose expression was also dampened in our
study, thus providing supporting evidence for possible involve-
ment of these candidate genes in CD4 T-cells as well. Heinig et al.
[38], in a systems-genetics study investigating rat tissues and
macrophages and human monocytes, discovered that the IRF7-
driven inﬂammatory network (which is enriched for innate
immune response genes) is associated with type 1 diabetes risk.
Interestingly, homologs of 9 of the genes belonging to this network
(Lcp2, Oas1a, Rtp4, Iﬁt1l, Iﬁt1, Ly6c1, Iﬁt3, Sp110, and Trim21) were
also repressed in NOD mice, suggesting a similar network may also
be altered in CD4 T-cells of NOD mice and might contribute to
diabetes development in the mouse. Similarly, in human T1D
studies, Elo et al. [39] found early suppression of immune response
gene expression in whole blood samples of children in the
prediabetic phase who eventually developed clinical diabetes.
Furthermore, Orban et al. [40] also found repression of all genes
that were differentially expressed in whole untreated human
peripheral blood CD4 T-cells from new onset T1D patients,
Table 8
Central genes in the Ingenuity Pathway Networks of the CD4 T-cell NOD altered genes.
Central Gene (IPA symbol) Gene symbol Total connections (no. of Focus genesa) Connected Focus genesa (shown as IPA symbols)
2 wk
HNF4A Hnf4a 27 (10) PLDN, NRD1, KHDRBS1, TMEM87A, SPATA5L1, RRM1,
ALDH5A1, RBM39, SNAP23, C1ORF109
IFNG Ifng 26 (2) CAPN3, Adaptor protein 1
IL4 IL4 26 (3) LCP2, GATM, Adaptor protein 1
TP53 Trp53 24 (4) TP53BP1, PRIM2, RRM1, PLTP
IL6 IL6 24 (2) LCP2, PLTP
MYC Myc 24 (1) DNMT3B
BCL2L1b Bcl2l1b 16 (2) GALNT10, RTN4
JUN Jun 16 (1) RBM39
IL15 IL15 13 (1) TRIM5
Prostaglandin E2 N/A 12 (1) ENPP3
NR3C1 Nr3c1 12 (1) TP53BP1
PARP1 Parp1 11 (1) ASCC3L1
APP App 11 (1) HBA2
EP300 Ep300 11 (1) SS18
HRAS Hras 9 (2) ENPP1, RTN4
3 wk
TNF Tnf 30 (6) OAS1, IFIT1L, LBP, NCOA3, PDRG1, BIRC6
TP53 Trp53 30 (7) TP53BP1, PRIM2, JDP2, PDRG1, BIRC6, DUT, NCOA3
IFNG Ifng 28 (5) CAPN3, RTP4, TRIM21, IFI27, OAS1
NFκB N/A 28 (4) ENPP1, LCP2, PNPT1, LBP
HNF4A Hnf4a 27 (14) PLDN, NRD1, KHDRBS1, TMEM87A, SPATA5L1, AHSA1,
NCOA3, LBP, TMEM87B, FXC1, KIAAO409, CCDC21,
PTPN18, PINK1
TGFB1 Tgfb1 26 (4) PI4K2B, ENPP1, NCOA3, PINK1
ERK Ephb2 25 (5) LCP2, DNMT3B, ANXA6, INPPL1, LBP
Beta-estradiol N/A 25 (6) IFIT1L, STC2, TCF15, NCOA3, PTP4A2, PINK1
p38MAPK Mapk14 23 (2) LBP, JDP2
IL4 IL4 22 (5) LCP2, GATM, IFIT1L, TRIM30, NCOA3
IGF1 Igf1 22 (5) KHDRBS1, INPPL1, NCOA3, TRPV2, MGA
RELA Rela 21 (3) COMMD7, PNPT1, NCOA3
IL15 IL15 19 (3) TRIM5, FKBP1A, PTP4A2
BCL2L1b Bcl2l1b 19 (3) GALNT10, RTN4, PNPT1
Prostaglandin E2 N/A 18 (1) ENPP3
4 wk
Interferon alpha Interferon alpha 34 (4) Oas, IFIT1L, RSAD2, OAS1
IFNG Ifng 33 (6) RTP4, LY6C1, Oas, OAS1, RSAD2, IFIT3
IL12 IL12 31 (3) TRIM30, LY6C1, IFIT1L
IL4 IL4 30 (5) LCP2, GATM, TRIM30, IFIT3, IFIT1L
IL6 IL6 27 (3) LCP2, IFIT1L, LY86
STAT4 Stat4 18 (2) IFIT1L, TRIM30
IL15 IL15 17 (1) TRIM5
Prostaglandin E2 N/A 16 (1) ENPP3
TP53 Trp53 14 (2) TP53BP1, PRIM2
BCL2L1b Bcl2l1b 14 (1) GALNT10
HNF4A Hnf4a 13 (5) PLDN, NRD1, KHDRBS1, TMEM87A, SPATA5L1
DDX58 Ddx58 11 (2) IFIT3, IFIT1L
SRCb Srcb 10 (2) KHDRBS1, PAQR7
E2F4 E2F4 10 (2) KHDRBS1, PRIM2
IFIT2 Iﬁt2 9 (1) IFIT3
a Genes that came from the list of NOD altered genes. The connections to each gene (i.e. edges representing gene-gene relationships) in the molecular networks were
manually counted. The central genes were then ranked from highest to lowest based on the number of total connections; the total # of connections represents the initial # of
edges prior to editing of the networks for better image visibility. The table shows the 15 topmost central genes and their immediately connected focus genes.
b BCL2L1 and SRC are located within the diabetes resistance region Idd13 (Chr2); BCL2L1 linked NOD altered genes (GALNT10, RTN4 and PNPT1) are all located on Chr11
(not in a known Idd) while SRC linked genes (PAQR7 and KHDRBS1) are both located on Chr4 (KHDRBS1 within the CD4 T-cell diabetogenic activity region Idd9/11 while
PAQR7 is not in a known Idd). Central or focus genes/molecules indicated in bold font were common to all 3 age groups. N/A – not applicable.
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including genes involved in key immune functions, such as
adhesion molecules lymphocyte function-associated antigen 1
(LFA-1) and P-selectin. Of note, L-selectin (the mouse homolog of
P-selectin) was also of signiﬁcantly lower expression in NOD
compared to C57 (p¼3.2e-06 and 0.0065 at 3 and 4 weeks,
respectively). Functional analyses by Orban et al. further indicated
that the CD4 T-cells were hyporesponsive to stimulation and
exhibited inhibition of cell cycle entry. In as much as the Orban
et al. microarray study investigated whole untreated CD4 T-cell
populations rather than antigen speciﬁc suggests that the
observed expression defect involves the polygenic CD4 T-cell
population, and thus may signify a global CD4 T-cell repression.
In support of this notion, other studies have also showed that CD4
T-cells from T1D patients have impaired activation (decreased
proliferation) to non-speciﬁc primary but not diabetes-speciﬁc
antigens [41]. It is worth noting that the human studies cited
above used peripheral blood samples providing further support for
the potential usefulness of CD4 T-cells from spleen (a peripheral
organ) in yielding results that may be of relevance to T1D. Thus,
future studies can test whether human peripheral blood cells
(which are readily accessible) carry similar defects as those
detected in our spleen CD4 T-cell study.
Similar to the study by Orban et al., we also investigated whole
untreated CD4 T-cells rather than antigen speciﬁc T cells. The
frequency of T cells with a given antigen speciﬁcity is usually very
low, estimated to be in the range of 1 or fewer in every 20,000 cells
[40]. Therefore, we argue that the defect detected in our study also
involves polygenic CD4 T-cells and is likely a basic genetic defect, in
the least for those changes that were observed at all 3 age points. We
cannot rule out the possibility that the differences observed, especially
the age-speciﬁc differences, may be due to inﬂuences other than
genetic defects, e.g. activation of islet speciﬁc CD4 T-cells, especially at
4 weeks of age. However, to this end, evaluation of our expression data
revealed no evidence of an activated phenotype in NOD mice,
suggesting that the changes in the gene expression may not be
attributed to auto-reactive cells. For example, expression of two
activation markers CD69 and CD38 was signiﬁcantly lower in NOD
(and NOR) compared to C57 (p¼8.26e-05 and 0.0056, respectively, at
4 weeks). CD69 expression was particularly interesting in that it
showed no signiﬁcant difference between the three species at 2 weeks
(p¼0.19) but became highly signiﬁcantly upregulated at 3 and 4weeks
in C57 (3-fold at each age, p¼4.57e-04 and 8.26e-05, respectively)
compared to both NOD and NOR. Obviously this result was not
reported in the "Section 3" as these types of changes were not the
focus of this paper. Notwithstanding, it gives further support to the
notion of a deﬁciency in T cell activation in the NOD mice, the effects
of which NOR overcomes likely due to presence of resistance genes.
Whereas the idea of a generalized repression of the immune
system may seem counterintuitive (since later stages of T1D are
dominated by inappropriate activation of autoreactive T-cells), it may
help explain previous observations that immunosuppression exacer-
bates autoimmune diabetes in NOD mice [42] while immunostimula-
tion circumvents it [43]. Furthermore, it may not be surprising that
relative reduction of gene expression was seen at the early stages
studied here, at which time tolerance would be induced. Of note,
tolerance to self antigens requires the activation of self-reactive
lymphocytes and their elimination by apoptosis as a result of this
activation. Furthermore, elimination of self-reactive lymphocytes in
the periphery also requires activation of the regulatory mechanisms
(such as regulatory T cells). Thus, both central and peripheral
tolerances are active processes that require normal mitochondrial
and metabolic function. Our gene Ontology and KEGG Pathway
analyses (Tables 5 and 6), together with the leukocyte study
[25], provided evidence for defects in mitochondria, metabolism,
antigen processing/presentation and T cell activation/function and
immune response. Furthermore, our preliminary functional studies
investigating the mitochondrial/metabolic defect found impaired
mitochondrial potential in NOD spleen leukocytes. All these data,
together with the literature discussed above, support the idea of a
global immune repression, which may lead to the breakdown of self-
tolerance in autoimmune diabetes. Indeed, a recent study, using a
mouse model of spontaneous autoimmune arthritis [44], suggested
that efﬁcient suppression of autoimmune diseases requires polyclonal
regulatory T cell speciﬁcities rather than single antigen-speciﬁcities.
Thus, we propose the following hypothesis. A genetic defect in
metabolism/mitochondria results in a global repression of the immune
system leading to a deﬁciency in immune tolerance, thus predisposing
NOD mice to autoimmunity. Analysis of changes in gene expression
and molecular pathways in NOD mice between different ages will
shade further light on the defects that directly accompany initiation of
insulitis, and subsequently development of diabetes. Furthermore, the
defects in antigen presenting cells (such as B cells, macrophages and
dendritic cells) may synergize with defects in the regulatory and
effector T-cells to create dyshomeostasis in the early stages of
autoimmune diabetes. Thus, investigation of the APC cell subsets is
also warranted to provide a more comprehensive picture of the
molecular pathophysiology of autoimmune diabetes.
The promoter and molecular pathway analyses (Tables 7 and 8)
identiﬁed several factors that may play a role in regulating the
above discussed defect. Several of these factors (Hnf4a, Ifng, Trp53,
Myc, IL15, Tnf, Tgfb1, beta-estradiol, IL6 and Ar) were also
identiﬁed by the spleen leukocyte study [25] indicating a strong
involvement of the CD4 T-cells in the unfractionated immune cells.
In addition, the current study identiﬁed novel regulators, including
Interferon alpha/beta, Irf1, Irf7, ISRE, IL12, and Stat4. Type 1 inter-
ferons regulate 3 (Irf1, Irf7, ISRE) of the 4 transcription regulators
identiﬁed in this study, suggesting a critical role for these
cytokines in regulating gene expression abnormalities in NOD
CD4 T-cells at the preinsulitis stage. Irf1 is well known to control
immune response gene expression [45] and has been demon-
strated to be an essential element (in addition to Ifng and IL12) in
the differentiation of naïve T cells [46,47]. Irf1 also functions as a
transcription activator of the Tnf receptor and of genes induced by
Ifng and type 1 interferons (including Irf7 and other ISGs) [45].
Together with the literature, our data provide support for a role for
Irf1 in regulating self-tolerance in autoimmune diabetes. Overall,
our study captured new information, which, combined with future
conﬁrmatory studies, will facilitate a CD4 T-cell systems-based
understanding of autoimmune diabetes and could ultimately lead
to the development of novel therapeutic strategies.
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